Antibody drug conjugates (ADC) could become the future of targeted therapy, according to Dr. Toshimitsu Uenaka, President of Eisai’s Epochal Precision Anti-Cancer Therapeutics (EPAT) Discovery Center. Check out the article he authored for Onco'Zine - The International Oncology Network to learn more about the potential role of ADCs in #cancer care. Link to the article: https://lnkd.in/gBVFAZGe
